An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

ABSTRACT: Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory-related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory-related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)-approved PAH therapies. This was a long-term, prospective, observational study. All respiratory-related AEs were recorded during the study. The number of PAH patients enrolled w

SUBMITTER: Zamanian RT 

PROVIDER: S-EPMC5019086 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature